UCB Ventures — Full Portfolio
8 tracked investments · listed companies and verified rows first
ExeVir develops multi-specific VHH antibody therapies to treat infectious diseases, immunological conditions, and oncology, with a focus on immunocompromised populations.
BiotechDeep TechDigital HealthHealthtechMedical DevicesGhent, BE
Xavier Saelens(Scientific Founder)Nico Callewaert(Scientific Founder)inMike Garrett(Chief Executive Officer)
Co-investorsV-Bio VenturesSambrinvestVIBFund+VIVES Partners
Iris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles.
BiotechDeep TechHealthtech
Megan Matthews(Co-founder & President)
Co-investorsVenrockPsyMed Ventures
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Si-Ping Han(Secretary)inDeepshikha Datta(Chief Executive Officer and President)
BoardKevin Zhang(Director)Dylan Morris(Director)in
Board seatAlicia Irurzun-Lafitte· per SEC Form D · $36M raise · filed Nov 2022
Co-investorsBold Capital PartnersCRV (Charles River Ventures)FREEFLOWGlobal BrainOno Venture Investment, Inc.Upfront Ventures+2 more
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)4BIO CapitalAmgen VenturesHatteras Venture PartnersJDRF T1D FundNorthpond Ventures+1 more
Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.
BiotechDeep TechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)
Co-investorsBerkeley FrontierIaso VenturesThe Column GroupYsios CapitalAlexandriaFidelity Investments+7 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound enhancing agents) to deliver genetic payloads to targeted sites in a redosable manner.
BiotechDeep TechDigital Health
Kenneth Greenberg(Founder)in
Co-investorsARCH Venture PartnersLeaps by BayerSymBiosisVida VenturesVivo Capital
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)
Co-investorsNovartis Venture FundRoche Venture FundSanofi VenturesYsios CapitalAsabys PartnersCriteria Bio Ventures+2 more
ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsCambridge Angels groupOxford Investment Opportunity Network (OION)4BIO CapitalOrigin Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.